EUVIMEDEUVIMED entdecken
Crossref

Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948

Kevin J Filipski iD, Luis A Martinez-Alsina, Matthew R Reese, Edelweiss Evrard, Leanne M Buzon, Kimberly O Cameron, Yuan Zhang iD, Karen J Coffman, James Bradow, Bethany L Kormos, Shenping Liu, John D Knafels iD und 22 weitere

Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 2466-2482

DOI: 10.1021/acs.jmedchem.4c02230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.11.2024. Verfasst von Kevin J Filipski und 33 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of branched-chain ketoacid dehydrogenase kinase (BDK or BCKDK), a negative regulator of branched-chain amino acid (BCAA) metabolism, is hypothesized to treat cardio-metabolic diseases. From a starting point with potential idiosyncratic toxicity risk, modification to a benzothiophene core and discovery of a cryptic pocket allowed for improved potency with 3-aryl substitution to arrive at PF-07328948, which was largely devoid of protein covalent binding liability. This BDK inhibitor was shown also to be a BDK degrader in cells and in vivo rodent studies. Plasma biomarkers, including BCAAs and branched-chain ketoacids (BCKAs), were lowered in vivo with enhanced pharmacodynamic effect upon chronic dosing due to BDK degradation. This molecule improves metabolic and heart failure end points in rodent models. PF-07328948 is the first known selective BDK inhibitor candidate to be examined in clinical studies, with Phase 1 single ascending dose data showing good tolerability and a pharmacokinetic profile commensurate with once-daily dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAnimalsHumansRatsStructure-Activity RelationshipMaleMiceDrug DiscoveryPhosphotransferases (Alcohol Group Acceptor)Rats, Sprague-DawleyDogsThiophenesProtein Kinases

Substanzen

(3-methyl-2-oxobutanoate dehydrogenase (lipoamide)) kinaseProtein Kinase InhibitorsPhosphotransferases (Alcohol Group Acceptor)ThiophenesProtein Kinases

Autor:innen und Institutionen

  • Pfizer Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States.
  • Pfizer Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States.

ORCID-Profile: Kevin J Filipski, Yuan Zhang, John D Knafels, Amit S Kalgutkar, Christine C Orozco

Zitieren

APA

Filipski, K. J., Martinez-Alsina, L. A., Reese, M. R., Evrard, E., Buzon, L. M., Cameron, K. O., Zhang, Y., Coffman, K. J., Bradow, J., Kormos, B. L., Liu, S., Knafels, J. D., Sahasrabudhe, P. V., Chen, J., Kalgutkar, A. S., Bessire, A. J., Orozco, C. C., Balesano, A., Cerny, M. A., …, & Esler, W. P. (2025). Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948. Journal of Medicinal Chemistry, 68(3), 2466-2482. https://doi.org/10.1021/acs.jmedchem.4c02230

Vancouver

Filipski KJ, Martinez-Alsina LA, Reese MR, Evrard E, Buzon LM, Cameron KO, et al. Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948. Journal of Medicinal Chemistry. 2025;68(3):2466-2482. doi:10.1021/acs.jmedchem.4c02230

BibTeX
@article{Filipski2025,
  author = {Filipski, Kevin J and Martinez-Alsina, Luis A and Reese, Matthew R and Evrard, Edelweiss and Buzon, Leanne M and Cameron, Kimberly O and Zhang, Yuan and Coffman, Karen J and Bradow, James and Kormos, Bethany L and Liu, Shenping and Knafels, John D and Sahasrabudhe, Parag V and Chen, Jie and Kalgutkar, Amit S and Bessire, Andrew J and Orozco, Christine C and Balesano, Amanda and Cerny, Matthew A and Bollinger, Eliza and Reyes, Allan R and Laforest, Brigitte and Rosado, Amy and Williams, George and Marshall, Mackenzie and Tam Neale, Kelly and Chen, Xian and Hirenallur-Shanthappa, Dinesh and Stansfield, John C and Groarke, John and Qiu, Ruolun and Karas, Spinel and Roth Flach, Rachel J and Esler, William P},
  title = {Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {3},
  pages = {2466--2482},
  doi = {10.1021/acs.jmedchem.4c02230}
}
Kostenlos starten →